Search results
Author(s):
Gilles W De Keulenaer
,
Dirk L Brutsaert
Added:
3 years ago
Definitions and Historical Considerations – The Misleading Role of Ejection Fraction
Chronic heart failure (CHF) is a heterogeneous syndrome with a complex pathophysiology. Although many different definitions for heart failure exist, we prefer the following: “a clinical syndrome characterised by symptoms and signs of increased tissue/organ water and decreased tissue/organ perfusion. Regardless…
View more
Author(s):
Otto A Smiseth
,
Anders Opdahl
,
Espen Boe
,
et al
Added:
3 years ago
Abstract
Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase…
View more
Author(s):
Desak Ketut Sekar Cempaka Putri
,
Andrianto Andrianto
,
Makhyan Jibril Al-Farabi
,
et al
Added:
1 year ago
Author(s):
Stefan Anker
,
Harriette Van Spall
Added:
2 years ago
Late-breaker host, Dr Harriette Van Spall (McMaster University, CA)is joined by Principal Investigator, Prof Stefan Anker (Charite Campus Virchow Clinic, DE) for an in-depth discussion on the latest data from the EMPEROR-Preserved trial presented at ESC Congress 2021.
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction evaluated the effects of…
View more
Michael Fu
Job title: Professor, Principal Investigator, Senior Consultant Physician/Cardiologist
Author
Amina Rakisheva
Job title: Consultant in Cardiology Department
Author
Christian Besler
Author
Author(s):
Scott Solomon
Added:
1 year ago
In this short interview, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, Boston, MA, US) discusses the design and baseline of the DELIVER trial.
This trial was designed to evaluate the effects of the dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection…
View more
Author(s):
Giuseppe Galati
Added:
3 years ago
Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) comments on the PARALLAX trial. Dr Galati compares the ESC hotline trial with PARAGON-HF.The PARALLAX study showed potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction.
Recorded remotely from Milan, 2020.
Recording Editors: Natascha Wienand & Tom Green
Editor: Mirjam Boros
View more
Ambarish Pandey
Job title: Assistant Professor in Internal Medicine
Author